ICICI Securities research report on Alkem Laboratories
Alkem Laboratories’ CEO, Dr. Vikas Gupta, is targeting double-digit revenue growth in the medium term, driven by strong hold in India (68% of sales), other international markets and new ventures. In India, it aims to grow 100-150bps faster than IPM as focused chronic therapies are growing at a faster pace with adequate growth supported by the acute portfolio. It acquired Bombay Ortho for INR 1.5bn in Apr’25 and entered into an in-licensing deal with Exactech for a foray in the fast-growing medtech space. Commercial operations at the new CDMO facility in the US will start in Q3FY26 and Alkem has a decent orderbook which could ensure swift pick-up and EBITDA breakeven in 12-18 months. We believe optimisation of RM cost and operating leverage may drive 100bps expansion in margins every year (25% margin targeted in medium term) while losses of new ventures may be curbed from H2FY27, helping it post ~200bps improvement in margins over FY25-28E.
Outlook
Transitory impact of opex of new ventures (annual opex of INR 2.4-3bn) and higher tax rate (35% from FY27) are already priced in, making the valuations attractive. Retain BUY with a revised TP of INR 6,400 (23x FY27E EV/EBITDA).
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
